Category: Gryphon

A report prepared for the U.S.-China Economic and Security Review Commission

In the past decade, China’s biotechnology industry has grown tremendously, fueled by Chinese government policies promoting the biotechnology sector as a driver of economic growth and increased foreign interaction with the U.S. and other countries. Gryphon Scientific, in partnership with Rhodium Group, performed an extensive investigation of China’s biotechnology industry and the role of U.S. companies in its development to assess the economic and security implications for the U.S. Our report provides a comprehensive look at a growing power in the global biotechnology industry and includes recommendations for specific steps to ensure continued vitality of the U.S. biotechnology industry and the security of our country.

The U.S. policy landscape for countering biological threats is split into two main groups: 1) biosecurity, which specifically focuses on preventing theft, diversion, or deliberate malicious use of biological sciences knowledge, skills, materials, and technologies to cause harm; and 2) biodefense, which involves the development of capabilities and knowledge to assess, detect, monitor, respond to, and attribute biological threats. This project involved the first ever systems-based analysis of the entire U.S. biosecurity and biodefense policy landscape, which enabled greater understanding of the functional relationships between policies as of 2017. These analyses, along with reviews of methodologies for measuring policy implementation and historical case studies to better understand factors that lead to opportunity costs, informed the development of a roadmap for implementing biosecurity and biodefense policies that leverages science and technology advances and minimizes security risks. In addition to the roadmap, this study presents two analytic frameworks for evaluating policy implementation and analyzing opportunity costs.

Supplements:

Executive Summary

Opportunity Cost Analysis Framework

Historical Case Studies for Opportunity Cost Analysis

Policy Case Study: Synthesis of the Horsepox Virus

Policy Evaluation Metrics Framework

Roadmap